retatrutide type 2 diabetes phase 2 trial Delivers Significant Hemoglobin A1C Reduction, Weight Loss in 3 Phase 2 trial results demonstrate

Our clinical team is here to support you

D.BuseJ

Adults who have struggled with weight loss despite diet and exercise Individuals who experience frequent hunger or difficulty controlling appetite Patients with signs of metabolic or hormonal challenges Those seeking a medically supervised weight loss program Individuals willing to participate in regular medical check-ins Patients looking for long-term weight management support Eligibility is determined by a licensed provider after a medical evaluation Who may Not be a Candidate

Previous studies have investigated GLP-1 receptor agonists in relation to brain-related pathways, but retatrutide simultaneously targets three metabolic receptors

"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." NEJM, 2016

Having obesity is one of the most visible diseases, and therefore it's highly stigmatized